Cargando…

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Detalles Bibliográficos
Autores principales:	Dubinsky, Marla C., Betts, Keith, Eren, Devrim, Tang, Wenxi, Yin, Lei, Gupte-Singh, Komal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212601/ http://dx.doi.org/10.1016/S0016-5085(22)61422-7

Ejemplares similares

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

784 CLINICAL COURSE OF PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS WITH POSITIVE COVID-19 ANTIBODY TESTING AT A SINGLE, TERTIARY CARE CENTER
por: Spencer, Elizabeth A., et al.
Publicado: (2021)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

Sa078 CLINICAL AND LABORATORY MARKERS DO NOT PREDICT DEEP HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS
por: Sharma, Disha, et al.
Publicado: (2021)

Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Sandlow, Sarah, et al.
Publicado: (2023)

EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE
por: Shiga, Hisashi, et al.
Publicado: (2022)

EP1277: EFFICACY OF CARBON DIOXIDE INSUFFLATION DURING COLONOSCOPY FOR PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL REMISSION -A RANDOMIZED TRIAL-
por: Otake, Yuriko, et al.
Publicado: (2022)

Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
por: Sandborn, William J, et al.
Publicado: (2021)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study
por: Sivasakthi, Priya, et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Su1094: HOSPITILISATIONS FOR NOROVIRUS DECREASE DURING THE COVID-19 PANDEMIC
por: Gottlieb, Max T., et al.
Publicado: (2022)

Su1076: DIVERTICULOSIS IS ASSOCIATED WITH INTERNAL HEMORRHOIDS ON COLONOSCOPY: POSSIBLE CLUES TO ETIOLOGY.
por: Sninsky, Jared A., et al.
Publicado: (2022)

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone
por: Vuyyuru, Sudheer K., et al.
Publicado: (2023)

Su083 PERSISTENCE OF GASTROINTESTINAL SYMPTOMS AFTER HOSPITALIZATION FOR COVID-19: PREVALENCE AND RISK FACTORS
por: Blackett, John W., et al.
Publicado: (2021)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1000: IMPACT OF COVID-19 PANDEMIC AND SOCIAL DETERMINANTS OF HEALTH ON UTILIZATION OF TELEHEALTH SERVICES
por: Sanaka, Harsha, et al.
Publicado: (2022)

Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis
por: Shaffer, Seth R., et al.
Publicado: (2021)

Su1270: CHRONIC PANCREATITIS AND COVID-19: INCIDENCE AND OUTCOMES. A MULTICENTER RESEARCH NETWORK ANALYSIS
por: Hadi, Yousaf, et al.
Publicado: (2022)

Su1003: IMPACT OF THE COVID-19 PANDEMIC ON HEALTHCARE ACCESS, DELIVERY AND VACCINATION IN PATIENTS WITH DIGESTIVE DISORDERS
por: Russin, Michelle, et al.
Publicado: (2022)

Su094 IMMUNE AND METABOLIC PATHOGENESIS OF ENVIRONMENTAL ENTERIC DYSFUNCTION IN CHILDHOOD UNDERNUTRITION: A BIRTH INCEPTION COHORT
por: Haberman, Yael, et al.
Publicado: (2021)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1496: SARS-COV-2 INFECTION IN IBD: PANDEMIC WAVES AND PREDICTORS OF SEVERE OR PERSISTENT COVID-19
por: Taxonera, Carlos, et al.
Publicado: (2022)

Su1067: LIVER ENZYMES ALTERATION BUT NOT GI SYMPTOMS ARE ASSOCIATED WITH DEATH IN MINORITY COVID-19 PATIENTS WITH CANCER
por: Oskrochi, Gholamreza, et al.
Publicado: (2022)

Su102 DIFFERENCES IN INTESTINAL EPITHELIAL GENE EXPRESSION MODULATES SARS-COV-2 INFECTION IN HUMAN IBD ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2021)

Su1501: PROPHYLACTIC VERSUS ENDOSCOPY DRIVEN TREATMENT OF CROHN'S POSTOPERATIVE RECURRENCE: A RETROSPECTIVE MULTICENTRIC EUROPEAN STUDY
por: Geldof, Jeroen, et al.
Publicado: (2022)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

Su1075: SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS
por: Kante, Bhaskar, et al.
Publicado: (2022)

Su1065: INCREASED INTEREST IN WEIGHT LOSS AND BARIATRIC INTERVENTIONS DURING THE COVID-19 PANDEMIC: AN ANALYSIS OF INTERNET SEARCH QUERIES
por: Rajan, Anjana, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Su1005: PRE-ENDOSCOPY CONSULTATION AND ADHERENCE TO OUTPATIENT ENDOSCOPY DURING COVID-19 PANDEMIC: IN-PERSON VISIT VERSUS TELEHEALTH
por: Musa, Abdullahi, et al.
Publicado: (2022)

Su093 GUT-BRAIN AXIS AND IRRITABLE BOWEL SYNDROME DURING SARS COV-2 PANDEMIC. A SURVEY BASED STUDY.
por: Piskorz, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p02mgq00473eicvcjcg0au38sq